PSC 04
Alternative Names: Adipose-derived allogeneic mesenchymal stem cells - Personalized Stem Cells; Allogeneic adipose stem cell therapy - Personalized Stem Cells; COVI-MSC™; PSC-04; STI-8282Latest Information Update: 02 May 2024
At a glance
- Originator Personalized Stem Cells
- Developer Sorrento Therapeutics
- Class Mesenchymal stem cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II SARS-CoV-2 acute respiratory disease
Most Recent Events
- 17 Apr 2024 Sorrento Therapeutics withdraws phase-IIa trial in Post-acute-COVID-19-syndrome at the unknown location (IV) before enrolment due to bankruptcy (NCT04992247)
- 09 Jan 2023 Sorrento Therapeutics terminates a Phase-II clinical trial in SARS-COV-2 acute respiratory disease in Brazil (IV), due to slow enrollments (NCT04903327)
- 18 Jan 2022 Brazilian regulatory agency (ANVISA) authorises phase II trial of PSC 04 in SARS-COV-2 acute respiratory disease